Farallon Capital Management

Renew Exim DMCC is owned by Valiant Investment DMCC.

Pentera is a leading provider of Automated Security Validation solutions. It empowers organizations to test the integrity of their cybersecurity layers across the entire attack surface continuously. By simulating real-world attacks, Pentera identifies genuine security vulnerabilities and guides remediation efforts.

Tectonic Therapeutic is a biotechnology company dedicated to advancing the discovery of novel drugs targeting G Protein-Coupled Receptors (GPCRs), historically considered challenging therapeutic targets. The company's proprietary platform, GEODe, enables the development of biologic medicines aimed at modifying disease progression in areas with significant unmet medical needs.

Founded in Vancouver in 1938 by John Prentice and L.L.G. Bentley, Canfor is a global leader in sustainable lumber production, employing over 5,000 people worldwide. Known for its product quality and customer service, the company operates mills across North America and Europe.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

AnaptysBio is a clinical-stage biotechnology company focused on developing therapeutic antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company's pipeline includes immune cell modulating antibodies such as rosnilimab, a PD-1 agonist in Phase 2b trials for rheumatoid arthritis and ulcerative colitis, and ANB032, a BTLA agonist in Phase 2b trial for atopic dermatitis.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Founded in 2006 by Jeffrey A. Goldberger and Andrew B. Cohen, Atlas Capital specializes in opportunistic and value-added real estate investments and developments, primarily focusing on gateway cities like New York and Los Angeles.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Tectonic Therapeutic is a biotechnology company dedicated to advancing the discovery of novel drugs targeting G Protein-Coupled Receptors (GPCRs), historically considered challenging therapeutic targets. The company's proprietary platform, GEODe, enables the development of biologic medicines aimed at modifying disease progression in areas with significant unmet medical needs.

Geron Corporation is a late-stage clinical biopharmaceutical company based in Menlo Park, California, specializing in the development and commercialization of therapeutics for hematologic malignancies. Established in 1990, the company is primarily focused on its investigational drug, imetelstat, a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. Imetelstat targets the uncontrolled proliferation of malignant progenitor cells, aiming to improve blood cell production in patients with conditions such as myelodysplastic syndromes and myelofibrosis. Geron generates revenue through collaboration agreements, milestones, royalties, and licensing arrangements, positioning itself as a key player in oncology therapeutics.

Spyre Therapeutics is a biotechnology company focused on developing innovative antibody therapies to transform the treatment of inflammatory bowel disease (IBD).

Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral, selective TYK2 inhibitor in Phase 1 trials for various autoimmune diseases.

Avidity Biosciences is a biopharmaceutical company developing antibody oligonucleotide conjugates to enable tissue-selective delivery and precision RNA therapies for serious diseases. Its AOC platform combines monoclonal antibody tissue targeting with oligonucleotide therapies to access previously undruggable tissues and genetic drivers. The lead candidate, AOC 1001, targets myotonic dystrophy type 1, and its muscle programs address muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. The pipeline also includes immune and other cell-type programs, including Del-zota for DMD, Del-desiran for DM1, and Del-brax for FSHD. Avidity is based in La Jolla, California.

Founded in 2015, HiBob develops Bob, an intuitive cloud-based HR management system designed for global, remote, and collaborative work environments. Bob empowers employees, fosters company culture, and maximizes employee experience through tools for time management, performance tracking, attendance records, compensation management, and more. Over 1,000 modern companies worldwide rely on Bob to drive organizational success.

Beta Bionics is a medical device company focused on diabetes care, developing and commercializing the iLet Bionic Pancreas System. The iLet uses adaptive closed-loop algorithms to automate insulin delivery and glucose management for people with insulin-requiring diabetes, with configurations that support bihormonal approaches. The company designs, manufactures, and markets the system to the diabetes community, aiming to simplify treatment and improve health outcomes by reducing the burden of daily insulin dosing and monitoring. Through its single-segment business model, Beta Bionics centers on bringing the iLet from development to commercialization.

Forte Biosciences is a biotechnology company specializing in dermatology. Its lead product, FB-401, is a topically applied live biotherapeutic developed with the National Institutes of Health and National Institute of Allergy and Infectious Diseases for treating inflammatory skin diseases.

Auna operates healthcare facilities and offers prepaid plans across Mexico, Peru, and Colombia. Its network comprises hospitals, clinics, and wellness centers, with a focus on oncology services in Peru.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

GreenYellow is a company that specializes in generating electricity through centralized power plants and decentralized photovoltaic projects. It offers solar panels and provides energy supply services to a diverse range of clients, including food and non-food retailers, government agencies, public utilities, and energy providers. The company's focus on energy efficiency includes operating energy efficiency contracts and offering monitoring services that help clients reduce their energy costs. By promoting solar photovoltaics and energy optimization, GreenYellow enables its customers to produce and manage clean energy, thereby creating value and providing a more affordable alternative to conventional energy sources.

Beta Bionics is a medical device company focused on diabetes care, developing and commercializing the iLet Bionic Pancreas System. The iLet uses adaptive closed-loop algorithms to automate insulin delivery and glucose management for people with insulin-requiring diabetes, with configurations that support bihormonal approaches. The company designs, manufactures, and markets the system to the diabetes community, aiming to simplify treatment and improve health outcomes by reducing the burden of daily insulin dosing and monitoring. Through its single-segment business model, Beta Bionics centers on bringing the iLet from development to commercialization.

Founded in Berlin in 2011 by doctors, scientists, and industry pioneers, Ada Health is a global health company dedicated to creating new possibilities for personal health management. Its core system connects medical knowledge with intelligent technology to empower individuals to actively manage their health and assist medical professionals in delivering effective care.

Better Therapeutics is a prescription digital therapeutics company focused on discovering, developing, and commercializing software-based solutions for cardiovascular and metabolic diseases. The company employs clinically-validated, FDA-regulated software to provide digital behavioral therapy aimed at altering the behaviors that contribute to these diseases. This approach is designed to enhance patients' quality of life, reduce reliance on medications, and lower healthcare costs. Better Therapeutics integrates neuroscience, lifestyle medicine, and explainable artificial intelligence into a mobile medical app that is prescribed by physicians. This app utilizes patient-generated data to guide clinical decision-making and improve treatment outcomes. Currently, the company's product pipeline includes therapeutic candidates targeting type 2 diabetes, hypertension, and dyslipidemia.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

Founded in 2015, HiBob develops Bob, an intuitive cloud-based HR management system designed for global, remote, and collaborative work environments. Bob empowers employees, fosters company culture, and maximizes employee experience through tools for time management, performance tracking, attendance records, compensation management, and more. Over 1,000 modern companies worldwide rely on Bob to drive organizational success.

Inbrace is a medical device company focused on revolutionizing orthodontic treatment with its innovative device that aligns teeth discreetly behind the teeth. This system utilizes patented self-guiding technology to apply continuous forces, allowing for gentle teeth correction while minimizing discomfort and reducing the frequency of dental visits compared to traditional methods. Inbrace aims to enhance patient confidence and satisfaction by addressing common concerns associated with orthodontic treatment. The company incorporates digital treatment planning, computer modeling, and direct digital manufacturing to provide a scalable, personalized solution that meets the diverse needs of orthodontic patients. With its FDA registration, Inbrace is positioned to disrupt the orthodontics market and drive practice growth for dental clinicians.

Founded in 1999, SomaLogic specializes in the discovery, development, and commercialization of life science research tools and clinical diagnostic products centered around its proprietary SOMAmer/SOMAscan technology. This platform enables protein measurement at scale, facilitating biomarker discovery for various diseases, drug development, and clinical diagnostics.

Zepz is an online money transfer service that enables individuals to send money to friends and family living abroad through computers, smartphones, or tablets. It provides a convenient and cost-effective alternative to traditional money transfer companies, which often charge high fees. Zepz allows users to send funds to over 140 destinations worldwide, including Europe, Asia, Africa, Australia, and the Americas. Recipients can receive money as bank deposits, cash pickups, Mobile Money, or mobile airtime top-ups. The platform is designed to facilitate secure international transfers, utilizing technology that allows customers to manage their funds efficiently, with lower processing fees compared to conventional methods. Zepz operates in 50 countries, aiming to simplify the process of remittance for its users.

Zentera Therapeutics is a biopharmaceutical company.

Point Biopharma Global Inc., established in 2019 and headquartered in Toronto, Canada, specializes in the development and commercialization of radioligand therapies for cancer treatment. The company's portfolio comprises several assets, including PNT2002, PNT2004, PNT2003, and PNT2001. Point Biopharma leverages its expertise in radioisotopes like Actinium-225 and Lutetium-177, along with advanced manufacturing technology and a patient-centric approach, to revolutionize theragnostic drug development and radioligand commercialization on a global scale.

GenapSys, Inc. develops innovative DNA sequencing technologies aimed at enhancing applied genomic testing and medical sequencing. Its primary product, the GenapSys Sequencer, utilizes a proprietary electrical-based detection method for single nucleotide incorporations, making it suitable for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. The sequencer is designed for versatility, allowing it to operate in various lab environments and automate clonal amplification. GenapSys is also focused on collaborating with local health agencies and researchers to facilitate rapid sequencing capabilities that can aid in controlling outbreaks. Its compact design enables deployment in diverse locations, such as hospitals and public transport hubs, for efficient virus sample analysis. Founded in 2010 and headquartered in Redwood City, California, GenapSys is committed to providing accessible and precise genetic testing solutions.

BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis through targeted protein degradation. It specializes in developing innovative small molecule degraders, initially targeting cancer, using its proprietary PRODEGY platform built upon expertise in Cereblon binding.

NeoGenomics Laboratories operates a network of cancer-focused testing facilities in the United States, Switzerland, and Singapore. The company is divided into two main segments: Clinical Services and Pharma Services. It provides a range of genetic and molecular testing services, including cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and molecular testing, aimed at helping clinicians and researchers understand cancer at a genetic level. Additionally, NeoGenomics offers morphologic analysis for diagnosis and supports pharmaceutical companies in their oncology programs through testing services that facilitate drug development and clinical trials. The company's collaboration with Inivata Limited for the commercialization of the InVisionFirst-Lung liquid biopsy test exemplifies its commitment to advancing cancer diagnostics. Founded in 2001 and headquartered in Fort Myers, Florida, NeoGenomics serves hospitals, pathologists, oncologists, academic centers, and other clinical laboratories, enhancing cancer care through innovative testing solutions.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

LUMICKS develops innovative technologies for studying biology and cancer at single-molecule and single-cell levels. Its products include C-Trap Optical Tweezers, Fluorescence Microscopy, and z-Movi Cell Avidity Analyzer, enabling real-time analysis of complex biological processes and interactions.

Theseus Pharmaceuticals is a biopharmaceutical company dedicated to enhancing the lives of cancer patients through the development of targeted therapies. The company focuses on discovering and commercializing innovative treatments that specifically address drug resistance mutations in critical driver oncogenes, which are genes that, when mutated, contribute to cancer progression. By leveraging advanced technology, Theseus Pharmaceuticals aims to transform cancer care and improve patient outcomes.

Orchard Therapeutics is a UK-based biopharmaceutical company dedicated to developing and commercializing innovative gene therapies for rare diseases. Its core focus is autologous ex vivo gene therapy, transforming hematopoietic stem cells into a gene-modified drug product for single-administration treatments. The company's portfolio includes Strimvelis, approved by the EMA in 2016, and several programs in advanced registrational studies across various disease areas.

Inivata Limited is a clinical cancer genomics company based in Cambridge, United Kingdom, that specializes in the analysis of circulating tumor DNA (ctDNA) to enhance cancer testing and treatment. Founded in 2014, Inivata has developed TAm-Seq technology, which enables the detection and analysis of genomic material from a patient's cell-free ctDNA, collected through non-invasive blood samples. This innovative approach, known as liquid biopsy, provides a significant advancement over traditional invasive biopsies by allowing for easier detection, monitoring, and treatment of cancer. Inivata's platform aims to assist oncologists in making informed treatment decisions by improving the understanding of cancer dynamics, including monitoring treatment responses and detecting relapses. The company has established a strategic collaboration with NeoGenomics, Inc. to further its mission in the field of cancer genomics.

DarioHealth is a digital health company that develops and commercializes patented and proprietary technology enabling smartphone-based laboratory testing and real-time diabetes management. Its flagship Dario system combines a mobile software application with a pocket-sized blood glucose monitoring device, backed by the DarioEngage platform that provides coaching, digital communications, alerts, trend analysis, and support for chronic illness management. The company markets its solutions directly to consumers and through retail pharmacies, hospitals, and distributors across international markets, with sales occurring online as well. DarioHealth operates at the intersection of life sciences, behavioral science, and software, delivering digital therapeutics-style interventions that are personalized and data-driven across diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health through a suite of software, devices, and coaching services. Established in 2011 and headquartered in Israel, DarioHealth focuses on transforming self-management of chronic conditions by integrating software, monitoring hardware, and remote coaching.

Beam Therapeutics is a biotechnology company developing precision genetic medicines using its proprietary base editing technology. Its focus includes therapies for hematological and genetic diseases, with ongoing programs targeting sickle cell disease, alpha-1 antitrypsin deficiency, and other serious conditions.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Founded in 1999, SomaLogic specializes in the discovery, development, and commercialization of life science research tools and clinical diagnostic products centered around its proprietary SOMAmer/SOMAscan technology. This platform enables protein measurement at scale, facilitating biomarker discovery for various diseases, drug development, and clinical diagnostics.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, that specializes in developing innovative medicines for various diseases, including cardiovascular, central nervous system, inflammatory, and metabolic disorders. Founded in 1997, the company focuses on pharmacology and pharmacokinetics, advancing several investigational drugs through clinical trials. Notable candidates include Etrasimod, which is in Phase III trials for ulcerative colitis and Phase IIb/III for Crohn’s disease, and Olorinab, currently in Phase IIb trials for abdominal pain linked to irritable bowel syndrome. Additionally, Arena is developing ralinepag for pulmonary arterial hypertension and APD418 for acute heart failure. The company has formed collaborations with several organizations, including United Therapeutics and Eisai, to enhance its research and expand its market presence. Arena Pharmaceuticals also has a marketed product, lorcaserin, approved for weight management, further demonstrating its commitment to addressing critical health challenges through innovative therapies.

Longboard Pharmaceuticals, Inc., established in 2020 and headquartered in San Diego, California, is engaged in developing optimized medicines targeting neurological diseases. The company focuses on improving pharmacology and pharmacokinetics to create novel treatments for rare conditions. Its pipeline includes LP352, a next-generation 5-HT2C agonist being evaluated for developmental and epileptic encephalopathies; LP143, a centrally acting CB2 receptor full agonist explored for potential treatment of neurological disorders like ALS and PD; and LP659, a highly selective S1P receptor modulator targeting multiple CNS neuroinflammatory disorders. Longboard operates as a subsidiary of Arena Pharmaceuticals, Inc., aiming to deliver these medicines to patients in need.

Kesoram Industries, founded in 1919 in Calcutta as Kesoram Cotton Mills, is an Indian diversified materials company. It began as a cotton textile producer and expanded into viscose rayon, transparent paper, and filament yarn under the Kesoram Rayon brand, and later added tyres and cement operations. Cement is marketed under the Birla Shakti brand. The company is headquartered in Kolkata and operates primarily in India, deriving the majority of its revenue there.

AUTO1 Group GmbH is a Berlin-based technology platform that specializes in the buying and selling of used cars. Founded in 2012, the company connects individual customers and professional car dealers through its digital marketplace, facilitating seamless transactions without the need for negotiation. AUTO1 Group sources used vehicles from various channels, including original equipment manufacturers and dealerships, and offers a certified and diverse inventory through its brands, such as AUTO1.com and Autohero.com. Operating in nearly 30 countries across Europe and North America, Auto1 Group serves both the retail market for private customers and the merchant segment for commercial car dealers. Its services include auction fees and logistics, ensuring a streamlined and transparent process in the used car trade.

Encoded Therapeutics is a biotechnology company focused on precision gene therapies to treat a broad range of severe genetic disorders. It develops therapies and a platform that identifies human genome sequences that regulate gene expression using screening and computational approaches. The company's pipeline targets conditions across multiple pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular disease, aiming to help medical practitioners treat patients and improve outcomes. Based in South San Francisco, California, Encoded Therapeutics was founded in 2014 and was previously known as Encoded Genomics.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

Atento is the largest provider of customer relationship management (CRM) and business process outsourcing (BPO) services in Latin America. The company offers a comprehensive range of services, including customer care, sales, collections, back office, and technical support, catering to various sectors such as telecommunications, banking, financial services, healthcare, retail, and public administration. Atento serves its clients through multiple channels, including digital platforms like SMS, email, chat, social media, and applications, as well as traditional voice and in-person interactions. The company operates across several geographical regions, including Brazil, the Americas, and EMEA (Europe, the Middle East, and Africa).

CargoX is a technology-driven freight marketplace based in Sao Paulo, Brazil, established in 2013. The platform connects shipping companies with a network of over 1.4 million trucks, effectively addressing the issue of excess capacity in the transportation sector. By providing real-time information on available truck capacity, CargoX enhances freight visibility and helps shippers identify optimal solutions for transporting a wide range of products throughout Brazil. This approach not only reduces shipping costs for clients but also increases earnings for truck drivers while minimizing CO2 emissions associated with empty trucks on the road.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing innovative therapies for fibrotic diseases. Its lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both indications and is currently undergoing Phase 2a clinical trials. The company is also developing PLN-1474, a small-molecule selective inhibitor of avß1, for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, which is in Phase 1 trials. Founded in 2015, Pliant Therapeutics is also advancing preclinical programs aimed at addressing oncology and muscular dystrophies.

Generation Bio is a genetic medicines company developing durable, redosable treatments for patients with rare and prevalent diseases. Its non-viral platform combines closed-ended DNA, cell-targeted lipid nanoparticles, and scalable manufacturing processes to deliver large and multiple genes across various tissues.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

Beta Bionics is a medical device company focused on diabetes care, developing and commercializing the iLet Bionic Pancreas System. The iLet uses adaptive closed-loop algorithms to automate insulin delivery and glucose management for people with insulin-requiring diabetes, with configurations that support bihormonal approaches. The company designs, manufactures, and markets the system to the diabetes community, aiming to simplify treatment and improve health outcomes by reducing the burden of daily insulin dosing and monitoring. Through its single-segment business model, Beta Bionics centers on bringing the iLet from development to commercialization.

ADVANCE.AI is a data-driven financial technology company operating in the APAC region, focused on transforming the credit system through innovative scoring methods. The company aims to create a more holistic and accurate alternative to traditional credit assessments, promoting a more democratic approach to credit evaluation. ADVANCE.AI develops a big-data platform that offers anti-fraud detection services, facilitating loan applications with features such as multi-platform detection, face recognition, identity verification, company assessments, and credit score analytics. This comprehensive suite of services enables businesses to reduce manual verification costs and enhance operational efficiency. The company's leadership comprises experienced entrepreneurs and investors from prestigious institutions and backgrounds, bringing expertise from significant financial and technological firms.

Full Truck Alliance is a Chinese company that operates a platform connecting shippers with truckers to facilitate the transportation of goods over various distances and cargo weights. The company provides comprehensive services to both shippers and truckers through its mobile and web platforms. Its primary source of revenue comes from the use of these platforms for freight matching services, as well as additional value-added services. By streamlining the logistics process, Full Truck Alliance aims to enhance efficiency in freight transportation within the region.

Meituan Bike, previously known as Mobike, is a Chinese bicycle-sharing service that operates a fully station-less model. Founded in January 2015 by Davis Wang Xiao Feng, Hu Wei Wei, and Xia Yi Ping, the company is headquartered in Beijing. Meituan Bike allows users to easily locate and rent bicycles through a mobile application, facilitating convenient transportation for short urban trips. The bicycles are equipped with smart locks and can be reserved via the app, offering a seamless user experience. In April 2018, the company was acquired by Meituan-Dianping for $2.7 billion and was rebranded as Meituan Bike in January 2019 as part of the integration process. The service has grown significantly since its inception, contributing to the development of urban mobility solutions in China.

Sea is a technology-driven consumer internet company operating in Southeast Asia, with a mission to enhance the lives of consumers and small businesses through innovative digital platforms. The company's core businesses include Shopee, a leading hybrid C2C and B2C e-commerce marketplace operating across seven countries; Garena, a gaming platform with Free Fire as its key revenue generator; and SeaMoney, offering financial services such as lending, payments, digital banking, and insurance.

The renewable energy arm of Hindustan Power Projects Pvt. Ltd .

PT Aplikasi Karya Anak Bangsa, commonly known as Gojek, is a mobile application-based platform founded in 2010 and headquartered in Jakarta, Indonesia. The company initially operated a motorcycle taxi fleet but has since evolved into a comprehensive Super App, offering a wide range of services including food delivery, transportation, digital payments, shopping, and various on-demand services such as massages. Launched in 2015, Gojek has rapidly become the largest consumer transactional technology group in Southeast Asia, driven by its commitment to speed, innovation, and social impact. The platform aims to empower the informal sector in the region while catering to diverse markets, including logistics, food, and entertainment.

Nexvet Australia Pty Ltd is a biopharmaceutical company based in Melbourne, Australia, specializing in the development of biological therapies for companion animals. Founded in 2010, Nexvet focuses on creating species-specific monoclonal antibodies to address chronic pain, immune oncology, chronic inflammation, and allergies in pets. The company's key products include Ranevetmab and Frunevetmab, which target nerve growth factor to alleviate pain associated with osteoarthritis in dogs and degenerative joint disease in cats, respectively. Additionally, Nexvet is developing NV-03, a monoclonal antibody for chronic joint pain in horses. Utilizing a unique technology called PETisation, Nexvet customizes therapies to specific species, enhancing the effectiveness and safety of treatments while minimizing immune responses. As a subsidiary of Zoetis Inc., Nexvet aims to transform animal medicine by collaborating with global partners in veterinary and human health to advance its innovative pipeline.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Youku is a prominent Chinese video-sharing platform that allows users to search, view, and share high-quality video content across various devices. The company employs a tri-networks integration model, offering a diverse range of online video content, including user-generated uploads, self-produced series, and licensed professional material. The platform serves as a space for individuals and institutions to share a variety of video creations, from personal moments to independent films and viral clips. Youku has established itself in the competitive digital entertainment landscape, facing rivals such as Tencent Video and Sohu Video. In 2012, Youku expanded its influence by acquiring Tudou, resulting in the formation of Youku Tudou, Inc. This strategic move enhanced its content library and user reach, further solidifying Youku's position in the online video market.

Sohu.com is a Chinese online media, games, and search company operating a network of web properties and an in-house search engine. Its offerings span online brand advertising, content and services across a matrix of sites including sohu.com, sogou.com, 17173.com, focus.cn, changyou.com, and tv.sohu.com, plus mobile news apps and portals. The company also develops and operates online games through its Changyou segment, with titles such as Tian Long Ba Bu, DDTank and Wartune. Sohu enables user-generated content and social interaction on its platforms and earns revenue from online advertising, information services, and gaming. Founded in 1995, the company expanded to mobile and video, becoming a key provider of Chinese online media, search, and gaming experiences for millions of users daily.

AdsIt is an online video advertisement provider based in Beijing, China.

Youku is a prominent Chinese video-sharing platform that allows users to search, view, and share high-quality video content across various devices. The company employs a tri-networks integration model, offering a diverse range of online video content, including user-generated uploads, self-produced series, and licensed professional material. The platform serves as a space for individuals and institutions to share a variety of video creations, from personal moments to independent films and viral clips. Youku has established itself in the competitive digital entertainment landscape, facing rivals such as Tencent Video and Sohu Video. In 2012, Youku expanded its influence by acquiring Tudou, resulting in the formation of Youku Tudou, Inc. This strategic move enhanced its content library and user reach, further solidifying Youku's position in the online video market.

Beijing Adsit Media Technology Co., Ltd. is a leading distribution platform for internet-based video advertisements in China. As the operating company and technology service provider for Baidu's TV business model, it holds a unique position as the sole strategic brand management partner for Baidu. The company specializes in offering a range of online video advertising services, including floating, embedded, and streaming video advertisements. These services are designed to help businesses attract customers and enhance revenue, leveraging Adsit Media's innovative technology and customized solutions tailored for advertising agencies.

Youku is a prominent Chinese video-sharing platform that allows users to search, view, and share high-quality video content across various devices. The company employs a tri-networks integration model, offering a diverse range of online video content, including user-generated uploads, self-produced series, and licensed professional material. The platform serves as a space for individuals and institutions to share a variety of video creations, from personal moments to independent films and viral clips. Youku has established itself in the competitive digital entertainment landscape, facing rivals such as Tencent Video and Sohu Video. In 2012, Youku expanded its influence by acquiring Tudou, resulting in the formation of Youku Tudou, Inc. This strategic move enhanced its content library and user reach, further solidifying Youku's position in the online video market.

E-House is a real estate services company in China offering a comprehensive online-to-offline (O2O) service platform. It offers primary sales agency services, online real estate services, real estate information and consulting services, real estate advertising services, real estate promotional event services, secondary real estate brokerage services, and real estate investment fund management services. E-House has served more than 80% of domestic real estate developers, including Vanke, Evergrande, Wanda, Longfor, Poly Real Estate, and many other real estate industry giants, and worked on more than 200,000 real estate projects. E-House was founded in 2004 and was first listed on the New York Stock Exchange in August 2007.

Heidi Coast Advertising Co., Ltd. is a Chinese company focused on the development and operation of campus media integrated marketing solutions. Heidi Coast Advertising’s leading brand, “China Campus Media,” covers new media such as campus video, campus outdoor, campus activity, CC176.com, and more. By cooperating with educational institutions and major domestic media organizations, the company spreads news, entertainment, programs, and advertisement information in universities and colleges, with students as the main audience group. It covers 18 economically developed cities and over 330 colleges and universities in China. It influences over 5 million people daily and maintains a campus broadcasting network.

Youku is a prominent Chinese video-sharing platform that allows users to search, view, and share high-quality video content across various devices. The company employs a tri-networks integration model, offering a diverse range of online video content, including user-generated uploads, self-produced series, and licensed professional material. The platform serves as a space for individuals and institutions to share a variety of video creations, from personal moments to independent films and viral clips. Youku has established itself in the competitive digital entertainment landscape, facing rivals such as Tencent Video and Sohu Video. In 2012, Youku expanded its influence by acquiring Tudou, resulting in the formation of Youku Tudou, Inc. This strategic move enhanced its content library and user reach, further solidifying Youku's position in the online video market.